# Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

> **NCT01213472** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 33 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)

## Key facts

- **NCT ID:** NCT01213472
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-31
- **Primary completion:** 2018-04-17
- **Final completion:** 2018-04-17
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213472, "Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01213472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*